|NYSE: LLY||Healthcare / Drug Manufacturers / USA|
|333.03||-0.5700||-0.17%||Vol 47.70K||1Y Perf 15.18%|
|Mar 21st, 2023 09:32 DELAYED|
|0.39 0.12%||- -|
|Target Price||384.00||Analyst Rating||Strong Buy 1.25|
|Potential %||15.11||Finscreener Ranking||★+ 43.25|
|Insiders Trans % 3/6/12 mo.||-100/-71/-71||Value Ranking||★ 39.48|
|Insiders Value % 3/6/12 mo.||-100/-94/-94||Growth Ranking||★★★★+ 60.86|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-93/-93||Income Ranking||★ 32.55|
|Price Range Ratio 52W %||52.23||Earnings Rating||Sell|
|Market Cap||317.16B||Earnings Date||27th Apr 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Apr 2023|
|Estimated EPS Next Report||1.67|
|EPS Growth Next 5 Years %||19.80|
|Avg. Weekly Volume||4.78M|
|Avg. Monthly Volume||3.56M|
|Avg. Quarterly Volume||2.99M|
Eli Lilly and Company (NYSE: LLY) stock closed at 333.6 per share at the end of the most recent trading day (a 1.34% change compared to the prior day closing price) with a volume of 3.41M shares and market capitalization of 317.16B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 19500 people. Eli Lilly and Company CEO is David A. Ricks.
The one-year performance of Eli Lilly and Company stock is 15.18%, while year-to-date (YTD) performance is -8.81%. LLY stock has a five-year performance of 326.38%. Its 52-week range is between 276.83 and 384.44, which gives LLY stock a 52-week price range ratio of 52.23%
Eli Lilly and Company currently has a PE ratio of 54.60, a price-to-book (PB) ratio of 34.25, a price-to-sale (PS) ratio of 15.65, a price to cashflow ratio of 43.00, a PEG ratio of 2.32, a ROA of 13.67%, a ROC of 24.78% and a ROE of 72.51%. The company’s profit margin is 20.28%, its EBITDA margin is 29.00%, and its revenue ttm is $21.24 Billion , which makes it $22.35 revenue per share.
Of the last four earnings reports from Eli Lilly and Company, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.67 for the next earnings report. Eli Lilly and Company’s next earnings report date is 27th Apr 2023.
The consensus rating of Wall Street analysts for Eli Lilly and Company is Strong Buy (1.25), with a target price of $384, which is +15.11% compared to the current price. The earnings rating for Eli Lilly and Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Eli Lilly and Company has a dividend yield of 1.29% with a dividend per share of $4.52 and a payout ratio of 47.00%.
Eli Lilly and Company has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.11, ATR14 : 7.95, CCI20 : 111.92, Chaikin Money Flow : -0.04, MACD : -1.82, Money Flow Index : 91.31, ROC : 5.89, RSI : 56.79, STOCH (14,3) : 94.77, STOCH RSI : 1.00, UO : 50.54, Williams %R : -5.23), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Eli Lilly and Company in the last 12-months were: Alonzo Weems (Option Excercise at a value of $0), Alonzo Weems (Sold 2 968 shares of value $932 361 ), Anat Hakim (Option Excercise at a value of $0), Anne Nobles (Option Excercise at a value of $0), Anne Nobles (Sold 5 000 shares of value $1 723 075 ), Daniel M. Skovronsky (Option Excercise at a value of $0), David A. Ricks (Option Excercise at a value of $0), Diogo Rau (Option Excercise at a value of $0), Donald A. Zakrowski (Sold 4 600 shares of value $1 422 362 ), Edgardo Hernandez (Option Excercise at a value of $0), Eric Dozier (Option Excercise at a value of $0), Jackson P. Tai (Buy at a value of $199 549), Jacob S. Van Naarden (Option Excercise at a value of $0), Johna L. Norton (Option Excercise at a value of $0), Leigh Ann Pusey (Option Excercise at a value of $0), Michael B. Mason (Option Excercise at a value of $0), Patrik Jonsson (Option Excercise at a value of $0)
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
CEO: David A. Ricks
Telephone: +1 317 276-2000
Address: Lilly Corporate Center, Indianapolis 46285, IN, US
Number of employees: 19 500
Tue, 21 Mar 2023 09:41 GMT Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Humana (HUM)- TipRanks. All rights reserved.
Mon, 13 Mar 2023 09:50 GMT Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Axsome Therapeutics (AXSM)- TipRanks. All rights reserved.
Tue, 21 Feb 2023 12:40 GMT Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Teladoc (TDOC) and Apellis Pharmaceuticals (APLS)- TipRanks. All rights reserved.
Tue, 21 Feb 2023 08:31 GMT Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Phibro Animal Health (PAHC) and Elanco Animal Health (ELAN)- TipRanks. All rights reserved.
Mon, 06 Feb 2023 16:31 GMT Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Regeneron (REGN) and Seagen (SGEN)- TipRanks. All rights reserved.
Fri, 03 Feb 2023 12:30 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Merck & Company (MRK)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.